Member Info for uinsionn

well entry is cheap here considering this is a potential turnaround story, been gathering, Lombard provide the opp, they been selling everywhere so not a reflection on any company just there compny focus now is to sell accross the board, this has huge upside potential, one contact market wise says if the get certain things right within the business we could be looking at 25-30m mcap which is huge upside from here and broker target of 5p. Defo worth a buy down here

sorry wrong Davis hall owns 17.58% of the company

Davis Hall owns 22% of the company

Moved the bid up again, got to be filling an order no other reason to do this, not attracting the sell volumes they require lower

Sounds like a great offer might get my ramping shoes on

must have been your post mate looks lie someone in a rush to get in before the weekend lol

Book just flipped looks like my timing was good, seller must be cleared time for the move back up to 10p

Today mate

increased my holding here, was a buyer yesterday on the 6p volume bought more today, no brainer considering the 10p placing and whats in play here

Well the share gathering continues, picked up another chunk myself yesterday, why not at these prices, AGM in June, so could see a couple of news items before then, they tend to do that near the agm

https://osf.io/gxe7v Papers are here for all to read

Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung
Impairment in Patients with COVID-19
Teluguakula Narasaraju1,
Chow5 and Marko Radic6*.
Benjamin M. Tang2, Martin Herrmann3, Sylviane Muller4, Vincent TK
1College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma USA.
2Department of Intensive Care Medicine, Nepean Hospital, Sydney, Australia.
3Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
4CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France/Laboratory of Excellence Medalis, Institut de science et d’ingénierie supramoléculaire, and University of Strasbourg Institute for Advanced Study (USIAS), 67000 Strasbourg, France.
5Department of Microbiology and Immunology, School of Medicine, National University of Singapore, National University Health System, Singapore.
6Department of Microbiology, Immunology and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Targeting neutrophils and NETs-associated lung injury in patients with severe COVID-19.
Administration of drugs that prevent neutrophil recruitment and activity may effectively attenuate the pathologic complications of alveolitis and vascular injury in patients with COVID-19, and initial results of several treatment strategies have been reported.8 One early randomized clinical trial was the infusion of vitamin C in patients with COVID-19, based on the hypothesis that vitamin C suppresses neutrophil influx, activation, and NET-associated alveolar-capillary damage.41 Although vitamin C exhibits anti-oxidant function, its effect on reducing neutrophil activity and NETs-mediated pathologies in vivo may be limited. In contrast, small molecules and peptides may reduce NET release in important ways. This is the case of peptide P140, which prevents NET release in vitro42. This peptide regulates chaperone- mediated autophagy and macroautophagy, thereby reducing excessive inflammation in animal models and autoimmune patients. The effect of P140 on the neutrophil influx in the bronchoalveolar space requires further attention.

There isa huge difference between a failed trial and a failed drug, Lupuzor was very much a failed trial, that fact will be proved by Avion, sometimes the wrong base is taken for a trial, I have seen reviews from people who were in the trial and they never felt so well as when they were on Lupuzor, they were so unhappy this drug was taken away from them. This has very little side effects compared to the alternatives and is a key to having a long happy life

Stick a fork in one in four restaurants.

That’s the dire assessment from OpenTable’s CEO, who predicts a quarter of the eateries that are now closed or that are only doing take out during the pandemic won’t be able to reopen again once this is over. Indeed, David Chang’s Momofuku restaurant group announced Thursday that it’s closing two of its restaurants in New York and Washington, D.C.

Steve Hafner, CEO of the Booking Holdings’ online reservation service and travel site Kayak, told Bloomberg that getting restaurants up and running again is a difficult recipe.

It was removed lol,there was more than one lol

They should really check the hygiene ratings too, some low scoring stuff which I identified early doors was ignored, other discount companies wouldn’t allow companies with 1 or 2 star hygiene ratings be on their sites, but I suppose beggars cant be choosers

The owner of Bella Italia, Cafe Rouge and Las Iguanas has said it plans to appoint administrators, putting the future of 6,000 workers in doubt.

Targeting neutrophils and NETs-associated lung injury in patients with severe COVID-19.
Administration of drugs that prevent neutrophil recruitment and activity may effectively attenuate the pathologic complications of alveolitis and vascular injury in patients with COVID-19, and initial results of several treatment strategies have been reported.8 One early randomized clinical trial was the infusion of vitamin C in patients with COVID-19, based on the hypothesis that vitamin C suppresses neutrophil influx, activation, and NET-associated alveolar-capillary damage.41 Although vitamin C exhibits anti-oxidant function, its effect on reducing neutrophil activity and NETs-mediated pathologies in vivo may be limited. In contrast, small molecules and peptides may reduce NET release in important ways. This is the case of peptide P140, which prevents NET release in vitro42. This peptide regulates chaperone- mediated autophagy and macroautophagy, thereby reducing excessive inflammation in animal models and autoimmune patients. The effect of P140 on the neutrophil influx in the bronchoalveolar space requires further attention.

Are very good here, don’t even mind negative comments as it keeps people’s feet on the ground, I am a story at price investor/trader I was initially in here for the trade and while doing my DD I saw a bigger picture and possibly a much higher return, I have taken a strong position here about 5/6 weights here now and happy to see how it unfolds, nice to be in at an average now of about 13.5p will average upwards if I continue to see potential in the story, but keep my average in good enough state to give me a non daily focus on share price.

The Board has been focused on delivering a business strategy, which provides the optimum route forward for ImmuPharma and its shareholders, based on its current assets, knowhow, collaborations and funding. In the medium term, we remain focussed on achieving the full regulatory approval of Lupuzor™ in conjunction with our US partner, Avion, which we believe has the potential to be a ground breaking drug for lupus patients with blockbuster potential in commercial terms. Both companies are focused on expediting Lupuzor™ into a new optimised international Phase III study. Avion's strengthening of its team of advisors to include a collaboration with a leading lupus patient group and the formation of KOLs, all of whom are senior respected consultants within the lupus and autoimmune community in the US and Europe, only enhances this strategy. In parallel, discussions are continuing with a number of potential commercial partners for Lupuzor™ outside of the US.